Barbara L. Jones | Authors

April 01, 2014

More than two dozen abstracts at the December 2013 meeting of the American Society of Hematology (ASH) focused on the detection, measurement, or monitoring of MRD in patients with multiple myeloma.

March 26, 2014

In most malignancies, early detection and intervention are prerequisites for a possible cure. Consequently, why is the standard of care for myeloma a watch-and-wait approach, with no treatment until progression?

February 26, 2014

Although the current standard of care for advanced NSCLC remains platinum doublet chemotherapy, recent evidence suggests that most newly diagnosed patients may be candidates for targeted therapy as firstline treatment.

December 03, 2013

Between 2007 and 2011, a collaboration among clinical oncologists, pathologists, and industry scientists led to the identification of a new molecularly defined subset of NSCLC, followed by the finding that crizotinib, then under development as a MET inhibitor, was an inhibitor of ALK.

November 21, 2013

T-VEC, a novel oncolytic immunotherapy derived from the herpes simplex virus type 1, demonstrated a significant improvement in DRR, the primary endpoint in a pivotal phase III trial in patients with stage IIIB-IV melanoma.

November 21, 2013

MPDL3280A produced durable responses in studies in patients with forms of locally advanced/metastatic cancers, including smokers with NSCLC who customarily have poorer responses to cancer therapies than nonsmokers.